Name : Human TRAIL R4/TNFRSF10D Protein
Product Source :
Recombinant Human TRAIL R4/TNFRSF10D Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Ala56-His211.[Accession | Q9UBN6]
Molecular Weight :
The protein has a predicted MW of 19.4 kDa. Due to glycosylation, the protein migrates to 38-45 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by SEC-HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human TRAIL R4 on Tris-Bis PAGE under reduced conditions. The purity is greater than 95%. SEC-HPLC The purity of Human TRAIL R4 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Human TRAIL, No Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Human TRAIL R4, His Tag with the EC50 of 76.1ng/ml determined by ELISA (QC Test). SPR Data Human TRAIL R4, His Tag immobilized on CM5 Chip can bind Human TRAIL, No Tag with an affinity constant of 0.13 nM as determined in SPR assay (Biacore T200).
Background :
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages.
Synonyms :
CD264; RSF10D; TRAILR4; DCR2; TRUNDD; TNFRSF10D
References & Citations :
(1)Werner TA, Nolten I, Dizdar L, Riemer JC, Schütte SC, Verde PE, Raba K, Schott M, Knoefel WT, Krieg A. IAPs cause resistance to TRAIL-dependent apoptosis in follicular thyroid cancer. Endocr Relat Cancer. 2018 Mar;25(3):295-308. doi: 10.1530/ERC-17-0479. Epub 2018 Jan 9. PMID: 29317481.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
Serpin A3 Proteinsite
KRAS ProteinSpecies
Popular categories:
B7-H3/CD276
DC-SIGN/CD209